Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.

Otvos L Jr, Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J, Surmacz E.

BMC Biotechnol. 2011 Oct 5;11:90. doi: 10.1186/1472-6750-11-90.

2.

Identification of adipokine receptor agonists and turning them to antagonists.

Otvos L Jr.

Methods Mol Biol. 2013;1081:195-209. doi: 10.1007/978-1-62703-652-8_12.

PMID:
24014441
3.

A novel leptin antagonist peptide inhibits breast cancer growth in vitro and in vivo.

Catalano S, Leggio A, Barone I, De Marco R, Gelsomino L, Campana A, Malivindi R, Panza S, Giordano C, Liguori A, Bonofiglio D, Liguori A, Andò S.

J Cell Mol Med. 2015 May;19(5):1122-32. doi: 10.1111/jcmm.12517. Epub 2015 Feb 27.

4.
5.

Adiponectin pathway attenuates malignant mesothelioma cell growth.

Niu K, Asada M, Okazaki T, Yamanda S, Ebihara T, Guo H, Zhang D, Nagatomi R, Arai H, Kohzuki M, Ebihara S.

Am J Respir Cell Mol Biol. 2012 Apr;46(4):515-23. doi: 10.1165/rcmb.2011-0068OC. Epub 2011 Nov 17.

PMID:
22095628
6.

Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling.

Otvos L Jr, Kovalszky I, Olah J, Coroniti R, Knappe D, Nollmann FI, Hoffmann R, Wade JD, Lovas S, Surmacz E.

Biopolymers. 2015 May;104(3):156-66. doi: 10.1002/bip.22627.

PMID:
25683126
7.

Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies.

Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, Kiess W, Mantzoros CS.

J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8. Epub 2006 Dec 27.

PMID:
17192291
8.

Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice.

Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ, Xu A.

Cancer Res. 2006 Dec 1;66(23):11462-70.

9.

Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets.

Khan S, Shukla S, Sinha S, Meeran SM.

Cytokine Growth Factor Rev. 2013 Dec;24(6):503-13. doi: 10.1016/j.cytogfr.2013.10.001. Epub 2013 Oct 21. Review.

PMID:
24210902
10.

Statin reverses reduction of adiponectin receptor expression in infarcted heart and in TNF-alpha-treated cardiomyocytes in association with improved glucose uptake.

Saito Y, Fujioka D, Kawabata K, Kobayashi T, Yano T, Nakamura T, Kodama Y, Takano H, Kitta Y, Obata JE, Kugiyama K.

Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3490-7. Epub 2007 Sep 28.

11.

Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis.

Nakayama S, Miyoshi Y, Ishihara H, Noguchi S.

Breast Cancer Res Treat. 2008 Dec;112(3):405-10. Epub 2007 Dec 28.

PMID:
18163210
12.

Function of RasGRP3 in the formation and progression of human breast cancer.

Nagy Z, Kovács I, Török M, Tóth D, Vereb G, Buzás K, Juhász I, Blumberg PM, Bíró T, Czifra G.

Mol Cancer. 2014 Apr 29;13:96. doi: 10.1186/1476-4598-13-96.

13.

Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.

Speyer CL, Smith JS, Banda M, DeVries JA, Mekani T, Gorski DH.

Breast Cancer Res Treat. 2012 Apr;132(2):565-73. doi: 10.1007/s10549-011-1624-x. Epub 2011 Jun 17.

14.

Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.

Anbalagan M, Ali A, Jones RK, Marsden CG, Sheng M, Carrier L, Bu Y, Hangauer D, Rowan BG.

Mol Cancer Ther. 2012 Sep;11(9):1936-47. doi: 10.1158/1535-7163.MCT-12-0146. Epub 2012 Jul 10.

15.

Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases.

Yamauchi T, Kadowaki T.

Int J Obes (Lond). 2008 Dec;32 Suppl 7:S13-8. doi: 10.1038/ijo.2008.233. Review.

PMID:
19136982
16.

Gold(III)-dithiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia.

Nardon C, Schmitt SM, Yang H, Zuo J, Fregona D, Dou QP.

PLoS One. 2014 Jan 2;9(1):e84248. doi: 10.1371/journal.pone.0084248. eCollection 2014.

17.

Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice.

Moon HS, Liu X, Nagel JM, Chamberland JP, Diakopoulos KN, Brinkoetter MT, Hatziapostolou M, Wu Y, Robson SC, Iliopoulos D, Mantzoros CS.

Gut. 2013 Apr;62(4):561-70. doi: 10.1136/gutjnl-2012-302092. Epub 2012 Jun 26.

PMID:
22735569
18.

The adiponectin receptors AdipoR1 and AdipoR2 activate ERK1/2 through a Src/Ras-dependent pathway and stimulate cell growth.

Lee MH, Klein RL, El-Shewy HM, Luttrell DK, Luttrell LM.

Biochemistry. 2008 Nov 4;47(44):11682-92. doi: 10.1021/bi801451f. Epub 2008 Oct 9.

19.

Insulin decreases myocardial adiponectin receptor 1 expression via PI3K/Akt and FoxO1 pathway.

Cui XB, Wang C, Li L, Fan D, Zhou Y, Wu D, Cui QH, Fu FY, Wu LL.

Cardiovasc Res. 2012 Jan 1;93(1):69-78. doi: 10.1093/cvr/cvr273. Epub 2011 Oct 19.

PMID:
22012952
20.

Globular adiponectin counteracts VCAM-1-mediated monocyte adhesion via AdipoR1/NF-κB/COX-2 signaling in human aortic endothelial cells.

Addabbo F, Nacci C, De Benedictis L, Leo V, Tarquinio M, Quon MJ, Montagnani M.

Am J Physiol Endocrinol Metab. 2011 Dec;301(6):E1143-54. doi: 10.1152/ajpendo.00208.2011. Epub 2011 Sep 6.

Supplemental Content

Support Center